Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
Xiuning Le(The University of Texas MD Anderson Cancer Center), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Kwan Ho Tang(AstraZeneca (Netherlands)), Jonathan W. Goldman(University of California, Los Angeles), Brayan Merchan Ruiz(AstraZeneca (Netherlands)), Adrianus J. de Langen(The Netherlands Cancer Institute), Christina S. Baik(Seattle Cancer Care Alliance), Paula G. Fraenkel(AstraZeneca (South Korea)), Byoung Chul Cho(Yonsei University), Zofia Piotrowska(Global Cancer Institute), Jonathan W. Riess(University of California Davis Medical Center), Noemı́ Reguart(Hospital Clínic de Barcelona), Paul E. Smith(Kansas State University), Yoshimasa Shiraishi(Kyushu University), Helen Ambrose(AstraZeneca (United Kingdom)), Sarah B. Goldberg(Yale University)
Cited by 5
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k